Nephrology
Article
FDA approves cefiderocol for multidrug-resistant, complicated urinary tract infections
The approval is for patients with limited or no alternative treatment options and includes a warning of Fetroja’s higher all-cause mortality rate...
Conference Coverage
New model for CKD risk draws on clinical, demographic factors
The equation has demonstrated high discrimination and variable calibration across a range of populations.
Conference Coverage
Patiromer allows more CKD patients to continue on spironolactone
PHILADELPHIA – After 12 weeks, 86% of the patiromer patients remained on spironolactone, vs. 66% of the placebo patients.
News
FDA adds diabetic kidney disease, heart failure indications to canagliflozin
This marks the first time in 20 years that a drug has been indicated for diabetic kidney disease treatment, according to the manufacturer.
From the Journals
USPSTF: Screening pregnant women for asymptomatic bacteriuria cuts pyelonephritis risk
But the new recommendations urge clinicians to refrain from testing asymptomatic nonpregnant women and adult men.
News
Farxiga gets Fast Track status from FDA
Conference Coverage
Urine albumin testing is crucial for patients at risk for CKD, but drop the 24-hour urine test
SAN DIEGO – An update on diagnosing, managing, and treating patients with comorbid hypertension and diabetes.
From the Journals
No increase in UTI risk with SGLT-2 inhibitors
compared...
Conference Coverage
DECLARE-TIMI58 shows improved kidney function with dapagliflozin
SAN FRANCISCO – The SGLT2 dapagliflozin was better than placebo at slowing down kidney disease in patients with type 2 diabetes
From the Journals
NOACs benefit early stage chronic kidney disease patients
NOACs reduced risk of several adverse events compared with VKAs in a meta-analysis of chronic kidney disease patients.
Latest News
The costs and benefits of SGLT2 inhibitors & GLP-1 RAs
The price tags on these drugs are the biggest barrier to their use.